Company news

Humacyte, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

September 15, 2025

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

August 7, 2025

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

July 23, 2025

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

July 8, 2025

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

June 9, 2025

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

June 2, 2025

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

May 19, 2025

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

May 9, 2025

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

March 28, 2025

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

March 26, 2025

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

March 25, 2025

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

March 25, 2025

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

March 10, 2025

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

March 3, 2025

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

February 27, 2025

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

February 27, 2025

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

February 26, 2025

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs

January 27, 2025

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

January 20, 2025

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

January 12, 2025

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

December 18, 2024

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

November 21, 2024

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

November 17, 2024

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

November 13, 2024

Humacyte Third Quarter 2024 Financial Results and Business Update

November 7, 2024

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

October 27, 2024

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

October 22, 2024

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

October 3, 2024

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

September 18, 2024

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

August 26, 2024

Humacyte Second Quarter 2024 Financial Results and Business Update

August 12, 2024

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

August 8, 2024

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

July 30, 2024

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

July 15, 2024

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

June 30, 2024

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

June 24, 2024

Humacyte First Quarter 2024 Financial Results and Business Update

May 9, 2024

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

March 21, 2024

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

February 28, 2024

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma

February 8, 2024

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma

December 11, 2023

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

November 16, 2023

Humacyte Third Quarter 2023 Financial Results and Business Update

November 8, 2023

Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model

October 15, 2023

Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma

September 11, 2023

Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8: 00 AM ET

September 10, 2023

Humacyte Second Quarter 2023 Financial Results and Business Update

August 13, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel™ (HAV™)

August 2, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.